← Back
May 14, 2026
May 23, 2023
Research
DxTerity Partners wih Lupus Research Alliance for 5 Year Landmark Study
Launch of Groundbreaking Lupus Landmark Study by Lupus Research Alliance and Lupus Therapeutics
Los Angeles, CA., May 23, 2023 – DxTerity Diagnostics today announced its collaborators The Lupus Research Alliance and Lupus Therapeutics have launched the Lupus Landmark Study, a 5-year prospective, longitudinal study. The Landmark study is targeting the prospective enrollment of up to 3500 adults diagnosed with systemic lupus erythematosus (SLE).
The study looks to provide real world data and clinical samples from patients living with lupus. The samples and data will enable evaluation of the effectiveness of therapies and power the development of precision medicine for SLE.
DxTerity Diagnostics will be providing testing of patients with its Modular Immune Profile (MIP) assay includes gene signatures for Type 1 Interferon (IFN-1), B-cells, T-cells, Plasmablasts/Plasma Cells, Low Density Granulocytes/Neutrophils, Plasmacytoid Dendritic cells, Monocytes, T-cell Exhaustion, Interferon Beta, Interferon Gamma, and Cellular Energy. The study will use DxTerity’s DxCollect MicroCollection Device (MCD) for stabilization and ambient transport of fingerstick blood samples.
According to Bob Terbrueggen, PhD, Founder and CEO of DxTerity Diagnostics, “We are very excited to kick off the Landmark study. This study provides DxTerity with an unique opportunity to demonstrate the value of modular genomics for improving the management of SLE patients.”
About DxTerity
DxTerity Diagnostics is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity Diagnostics develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring. For more information, please visit www.dxterity.com.
Contact DxTerity Diagnostics Inc.
Name: Jim Healy
Phone: 310-537-7857
Email: info@dxterity.com
Clinical data supporting anifrolumab
Anifrolumab obtained FDA approval through results from TULIP-1 and TULIP-2 phase 3 clinical trials, demonstrating broad efficacy with improvements across multiple organ systems.
Related articles
Research
•
May 14, 2026
Precision Medicine using Modular Genomics
A simple look at how RNA-based testing can help uncover patterns in immune system activity and support more informed care decisions.
Research
•
February 27, 2020
DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device
Learn how patient-friendly testing can reduce barriers, improve convenience, and help people stay more connected to their health journey.
•
May 18, 2022
DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) for Systemic Lupus Erythematosus
IFN-1 gene signature testing represents the advancement of precision medicine beyond cancer in autoimmune disease
Stay in the know.
Get the latest updates and news.
DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being.
← Back
Research
•
May 23, 2023
DxTerity Partners wih Lupus Research Alliance for 5 Year Landmark Study
Launch of Groundbreaking Lupus Landmark Study by Lupus Research Alliance and Lupus Therapeutics
Los Angeles, CA., May 23, 2023 – DxTerity Diagnostics today announced its collaborators The Lupus Research Alliance and Lupus Therapeutics have launched the Lupus Landmark Study, a 5-year prospective, longitudinal study. The Landmark study is targeting the prospective enrollment of up to 3500 adults diagnosed with systemic lupus erythematosus (SLE).
The study looks to provide real world data and clinical samples from patients living with lupus. The samples and data will enable evaluation of the effectiveness of therapies and power the development of precision medicine for SLE.
DxTerity Diagnostics will be providing testing of patients with its Modular Immune Profile (MIP) assay includes gene signatures for Type 1 Interferon (IFN-1), B-cells, T-cells, Plasmablasts/Plasma Cells, Low Density Granulocytes/Neutrophils, Plasmacytoid Dendritic cells, Monocytes, T-cell Exhaustion, Interferon Beta, Interferon Gamma, and Cellular Energy. The study will use DxTerity’s DxCollect MicroCollection Device (MCD) for stabilization and ambient transport of fingerstick blood samples.
According to Bob Terbrueggen, PhD, Founder and CEO of DxTerity Diagnostics, “We are very excited to kick off the Landmark study. This study provides DxTerity with an unique opportunity to demonstrate the value of modular genomics for improving the management of SLE patients.”
About DxTerity
DxTerity Diagnostics is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity Diagnostics develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring. For more information, please visit www.dxterity.com.
Contact DxTerity Diagnostics Inc.
Name: Jim Healy
Phone: 310-537-7857
Email: info@dxterity.com
Related articles
Research
•
May 14, 2026
Precision Medicine using Modular Genomics
A simple look at how RNA-based testing can help uncover patterns in immune system activity and support more informed care decisions.
Research
•
February 27, 2020
DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device
Learn how patient-friendly testing can reduce barriers, improve convenience, and help people stay more connected to their health journey.
•
May 18, 2022
DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) for Systemic Lupus Erythematosus
IFN-1 gene signature testing represents the advancement of precision medicine beyond cancer in autoimmune disease
Stay in the know.
Get the latest updates and news.
DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being.